CMPS

COMPASS Pathways (CMPS) drew fresh attention after confirming a prominent role at the 2026 NEI Fall Congress, highlighting its COMP360 psilocybin program and an educational initiative focused on treatment-resistant depression for US clinicians.

COMPASS Pathways has delivered a powerful 3 year share price gain, even after a recent pullback, and fresh clinical progress on its lead therapy now puts the spotlight on whether that move still lines up with the company’s balance sheet.

COMPASS Pathways (CMPS) is back in focus after recent share price swings, with the mental health biotech drawing attention as investors reassess its psilocybin-based COMP360 pipeline and current valuation.

LONDON & NEW YORK, September 30, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today.

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potential U.S.

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its synthetic psilocybin treatment in treatment-resistant depression, or TRD.

Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S.

Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a potential commercial launch for treatment-resistant depression in the first half of 2027.